Agios Pharmaceuticals Inc. (NASDAQ:AGIO) was down 4.4% on Wednesday . The company traded as low as $41.44 and last traded at $42.13, with a volume of 255,001 shares trading hands. The stock had previously closed at $44.05.

Several research analysts have commented on AGIO shares. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Wednesday, April 20th. SunTrust Banks Inc. started coverage on shares of Agios Pharmaceuticals in a research report on Tuesday, March 29th. They set a “buy” rating and a $57.00 price objective for the company. JPMorgan Chase & Co. upgraded shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $50.00 to $62.00 in a research report on Monday, June 13th. Credit Suisse Group AG restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Monday, April 25th. Finally, Vetr downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 price objective for the company. in a research report on Tuesday, June 7th. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $69.67.

The firm has a 50 day moving average price of $49.01 and a 200-day moving average price of $46.45. The company’s market cap is $1.57 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.18. The company had revenue of $31.30 million for the quarter, compared to the consensus estimate of $20.94 million. During the same period in the prior year, the company earned ($0.13) earnings per share. The firm’s revenue was down 8.5% on a year-over-year basis. Equities analysts expect that Agios Pharmaceuticals Inc. will post ($3.46) EPS for the current year.

In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the firm’s stock in a transaction that occurred on Tuesday, April 26th. The shares were sold at an average price of $53.44, for a total value of $133,813.76. Following the completion of the transaction, the director now directly owns 128,429 shares of the company’s stock, valued at approximately $6,863,245.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Scott Biller sold 27,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total transaction of $1,787,500.00. Following the completion of the transaction, the insider now directly owns 81,376 shares of the company’s stock, valued at $5,289,440. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. Jennison Associates LLC increased its position in Agios Pharmaceuticals by 170.6% in the fourth quarter. Jennison Associates LLC now owns 430,085 shares of the biopharmaceutical company’s stock valued at $27,921,000 after buying an additional 271,142 shares during the period. BB Biotech AG increased its position in Agios Pharmaceuticals by 2.4% in the fourth quarter. BB Biotech AG now owns 2,159,921 shares of the biopharmaceutical company’s stock valued at $140,222,000 after buying an additional 50,000 shares during the period. Mutual of America Capital Management LLC increased its position in Agios Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 17,325 shares of the biopharmaceutical company’s stock valued at $1,125,000 after buying an additional 86 shares during the period. GAM Holding AG increased its position in Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock valued at $2,967,000 after buying an additional 31,000 shares during the period. Finally, Columbia Wanger Asset Management LLC increased its position in Agios Pharmaceuticals by 11.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 436,994 shares of the biopharmaceutical company’s stock valued at $28,370,000 after buying an additional 44,861 shares during the period.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.